CORRECTING and REPLACING Enzon to Release Fourth Quarter 2009 Earnings on Wednesday, February 17, 2010; Conference Call and Webcast to Follow

BRIDGEWATER, N.J. -- (BUSINESS WIRE) -- Second graph, first sentence of release should read: Participating in the call from Enzon’s executive management team will be Jeffrey H. Buchalter, President and Chief Executive Officer ... (sted: Chairman and Chief Executive Officer).

The corrected release reads:

ENZON TO RELEASE FOURTH QUARTER 2009 EARNINGS ON WEDNESDAY, FEBRUARY 17, 2010; CONFERENCE CALL AND WEBCAST TO FOLLOW

Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) announced today that it will report its financial results for the quarter ended December 31, 2009, on Wednesday, February 17, 2010 at approximately 8:00 am Eastern Time (ET). The release will be followed by a live conference call, which will begin at approximately 10:00 am Eastern Time (ET) on Wednesday, February 17, 2010.

Participating in the call from Enzon’s executive management team will be Jeffrey H. Buchalter, President and Chief Executive Officer, and Craig Tooman, Executive Vice President, Finance and Chief Financial Officer.

All interested parties may access the call by using the following information:

The call will also be available live audio webcast at www.investorcalendar.com. Listeners should go to the website at least fifteen minutes before this event to download and install any necessary audio software. For those unable to attend the live audio webcast, a replay will be available beginning approximately one hour after the event. Additionally, a telephonic rebroadcast will also be available following the call. The rebroadcast will begin on Wednesday, February 17, 2010 at approximately 12:00 pm Eastern Time (ET) and end on Wednesday, February 24, 2010 at approximately 12:00 pm Eastern Time (ET). It may be accessed using the following information:

About Enzon

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of important medicines for patients with cancer and other life-threatening conditions. The Company’s drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform used to create product candidates with benefits such as reduced dosing frequency and less toxicity. Enzon’s PEGylation technology has created a royalty revenue stream from licensing partnerships for other products developed using the technology. Further information about Enzon and this press release can be found on the Company’s web site at www.enzon.com.